Chapter 3. Challenges Interpreting Cardiac Troponin Values

  1. James A. de Lemos MD Associate Professor of Medicine Coronary Care Unit Director
  1. Fred S. Apple PhD Medical Director Clinical Laboratories Professor

Published Online: 13 JAN 2009

DOI: 10.1002/9781444300208.ch3

Biomarkers in Heart Disease

Biomarkers in Heart Disease

How to Cite

Apple, F. S. (2008) Challenges Interpreting Cardiac Troponin Values, in Biomarkers in Heart Disease (ed J. A. de Lemos), Blackwell Publishing Ltd., Oxford, UK. doi: 10.1002/9781444300208.ch3

Editor Information

  1. University of Texas Southwestern Medical Center Dallas, TX, USA

Author Information

  1. Hennepin County Medical Center, Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, MN, USA

Publication History

  1. Published Online: 13 JAN 2009
  2. Published Print: 18 APR 2008

Book Series:

  1. The AHA Clinical Series

Book Series Editors:

  1. Elliott Antman

ISBN Information

Print ISBN: 9781405175715

Online ISBN: 9781444300208



  • challenges interpreting cardiac troponin values;
  • FDA-cleared cTn assay characteristics;
  • cardiac troponin values and serial monitoring;
  • non-ischemic etiologies and cTn increases;
  • cardiac disease with end-stage renal disease (ESRD);
  • congestive heart failure (CHF);
  • pulmonary embolism;
  • B-type natriuretic peptide (BNP) in patients with HF


This chapter contains sections titled:

  • Introduction

  • Universal acceptance of the 99th percentile value as the accepted cut-off

  • Utilization and interpretation of serial, timed cTn values

  • Non-ischemic etiologies of cTn increases

  • Conclusions

  • References